Transforming Clinical and Translational Research and Education at Rockefeller

改变洛克菲勒的临床和转化研究与教育

• 批准号: 7900121
• 负责人: Barry Coller
• 金额: $ 41.84万
• 依托单位: ROCKEFELLER UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-09 至 2012-09-08
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7900121
• 关键词: Transforming; Clinical; Translational; Research; Education

The Rockefeller University Hospital, a GCRC awardee since 1963, has been the continuous "home" for clinical and translational science at Rockefeller since 1910. It has been the site of numerous landmark scientific and clinical contributions, and many of its trainees have gone on to become academic leaders. With the new resources available under a Clinical and Translational Science Award (CTSA), a core faculty of. distinguished investigators, whose research spans the basic-translational spectrum and encompassesa broad range of scientific and medical disciplines, will integrate and expand their scientific and educational programs in a new Rockefeller University Center for Clinical and Translational Science. The new Center will transform clinical and translational research by encouraging new studies, and by enhancing and centralizing the support structures required to conduct studies with scientific rigor and an absolute commitment to protection of human subjects and participant safety. The key elements in the transformation will be: 1)A new governance structure reflecting the NIH cooperative agreement (U54) "assistance" mechanism, 2) Creation of a new K-12 Clinical Research Scholars Program offering Masters and PhD level degrees to complement the current Clinical Scholars,Program, 3) Infrastructure enhancements to facilitate the development and conduct of clinical protocols under the principle of Good Clinical Practice (GCP), including biomedical informatics, biostatistics. bionutrition, research nursing, research pharmacy, participant recruitment and community engagement, and regulatory support and oversight from the clinical research (research subject advocate) support office, 4) Development of innovative and novel core methodologies related to dendritic cell therapy; vaccine development for HIV, hepatitis C, and malignancies; genetics/genomics; assessing the immune response; and metabolic phenotyping. The Center will continue Rockefeller's tradition of focusing on the interface between scientific discovery, human pathophysiology,and novel diagnostic, preventive and therapeutic strategies. It will partner with industry, when mutually beneficial, to achieve these goals. The Center will also be an active member of the National CTSA Consortium, offering the Consortium novel ideas and tools for conducting and evaluating clinical and translational research. It will also eagerly adopt the best practices identified by the Consortium and adhere to the standardsset by the Consortium.

自1963年以来，洛克菲勒大学医院是GCRC的获奖者，一直是不断的“家” 自1910年以来，洛克菲勒（Rockefeller）的临床和转化科学。它一直是许多地标的所在地 科学和临床贡献，其许多学员已经成为学术领导者。和 根据临床和转化科学奖（CTSA）获得的新资源，这是一个核心教师。 杰出的研究人员，他们的研究跨越基本的翻译光谱和包含 广泛的科学和医学学科将整合和扩展其科学和教育 新洛克菲勒大学临床与转化科学中心的计划。新中心将 通过鼓励新的研究并通过增强和集中来改变临床和转化研究 进行科学严谨的研究所需的支持结构，并绝对承诺 保护人类受试者和参与者的安全。转换中的关键要素将是：1） 反映NIH合作协议（U54）“援助”机制的治理结构，2）创建 新的K-12临床研究学者计划，提供硕士学位和博士水平学位以补充 当前的临床学者，计划，3）基础设施增强功能，以促进发展和 良好临床实践原则（GCP）的临床方案的行为，包括生物医学 信息学，生物统计学。 Bionutrition，研究护理，研究药房，参与者招聘和 临床研究的社区参与以及监管支持和监督（研究主题 倡导者）支持办公室，4）开发与树突细胞有关的创新和新颖的核心方法论 治疗; HIV，丙型肝炎和恶性肿瘤的疫苗开发；遗传学/基因组学；评估 免疫反应；和代谢表型。该中心将继续洛克菲勒的关注传统 科学发现，人类病理生理学和新颖的诊断，预防和预防和 治疗策略。在互惠互利的情况下，它将与行业合作，以实现这些目标。这 中心还将是国家CTSA财团的活跃成员，提供财团的小说思想 以及进行和评估临床和转化研究的工具。它也将热切地采用最好的 财团确定的实践并遵守财团的标准集。